Tech Company Financing Transactions
Gritstone Oncology Funding Round
Casdin Capital, Clarus and Frazier Healthcare Partners participated in a $102 million Series A funding round for Gritstone Oncology. The funding round was announced by the company on 10/21/2015.
Transaction Overview
Company Name
Announced On
10/21/2015
Transaction Type
Venture Equity
Amount
$102,000,000
Round
Series A
Investors
Proceeds Purpose
The financing will support discovery and development of novel tumor-specific neo-antigen (TSNA) based immunotherapies, with an initial focus on lung cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5959 Horton St. 300
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Allen
Chief Financial Officer
Jean-Marc Bellemin
Chief Medical Officer
Raphaël Rousseau
Chief Scientific Officer
Karin Jooss
Chief Technical Officer
Roman Yelensky
VP - Bus. Development
Matthew Hawryluk
VP - Regulatory Affairs
Erin Jones
Browse more venture capital transactions:
Prev: 10/21/2015: Betabrand venture capital transaction
Next: 10/21/2015: Silk Road Medical venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs